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OBJECTIVES This study sought to determine the relationship of lipoprotein(a) (Lp(a)) and other cardiac
risk factors to coronary atherosclerosis as measured by calcification of coronary arteries in
asymptomatic postmenopausal women.
BACKGROUND Lipoprotein(a) is considered a risk factor for coronary heart disease. Coronary calcium
deposition is believed to be a useful noninvasive marker of coronary atherosclerosis in women.
However, to our knowledge, there are no reports of the relationship of Lp(a) to coronary
calcium in postmenopausal women.
METHODS In 178 asymptomatic postmenopausal women (64 6 8 years), we measured Lp(a) and other
cardiac risk factors: age, hypertension, diabetes, low-density lipoprotein cholesterol, smoking
status, body mass index, physical activity level and duration of hormone replacement therapy.
Electron-beam computed tomography was done to measure coronary calcium (calcium score).
We analyzed the relationship between calcium score and cardiac risk factors using multivar-
iate analysis.
RESULTS Although calcium score correlated with traditional risk factors of age, diabetes, hypertension
and smoking, it did not correlate with Lp(a) in the asymptomatic postmenopausal women.
Similar multivariate analyses were done in the subjects age .60 years and in the subjects with
significant coronary calcium deposit (calcium score $50). These analyses also have failed to
show an association of levels of Lp(a) with coronary calcium deposits.
CONCLUSIONS We conclude that in asymptomatic postmenopausal women, Lp(a) levels do not correlate with
coronary atherosclerosis as measured by coronary calcium deposits. (J Am Coll Cardiol 2000;
35:314–20) © 2000 by the American College of Cardiology
Electron-beam computed tomography (EBCT), which al-
lows accurate quantification of coronary calcium (1,2), has
been investigated as a tool for noninvasive detection of
coronary heart disease (CHD) (3,4) and is considered by
some to be a screening method (3–5) predictive of future
cardiac events (6). It has been suggested to be especially
useful for diagnosis of CHD in women (7), particularly as
exercise testing has been shown to be less accurate in women
than men for diagnosis of CHD (8). Pathologic studies have
documented a close correlation between coronary calcium
and atherosclerotic plaque (9–12) with high sensitivity of
coronary calcium for predicting advanced lesions. Patho-
logic studies done in young adults who have died from
noncardiac causes show coronary calcium deposits and
atherosclerotic plaque, suggesting the potential value of
calcium as an early marker of CHD (13).
Lipoprotein(a) (Lp[a]) consists of a low-density lipopro-
tein (LDL) particle to which the protein (a) moiety is bound
by a disulfide bond to apolipoprotein B-100. The (a) protein
is a hydrophilic glycoprotein that has considerable sequence
homology with plasminogen. These features implicate
Lp(a) both directly in atherogenesis and in inhibition of
fibrinolysis. A high concentration of Lp(a) is thought to be
an independent risk factor for cardiovascular (14–18), ce-
rebrovascular (15,17,19) and thoracic aortic atherosclerosis
(20). It is known that Lp(a) levels increase after the
menopause (21) and thus may correlate with the higher
incidence of atherosclerosis in this age group. As heart
disease is the leading cause of death in women, and women
have higher mortality after advent of clinical CHD (22–24),
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it is important to identify all risk factors for CHD in women
so that cardiac risk can be more accurately determined and
more aggressive prevention strategies can be targeted to
high-risk women. The purpose of this study was to deter-
mine whether high levels of Lp(a) are associated with
coronary calcium deposits, a marker for coronary atheroscle-
rosis, in asymptomatic postmenopausal women. The role of
EBCT as a screening tool in asymptomatic patients with
conventional risk factors has been of great interest recently,
as some studies suggest that EBCT may have a role in
detecting early disease (6).
METHODS
Subjects. Between April 1995 and August 1997, 178
asymptomatic postmenopausal women (64 6 8 years) were
enrolled in the Females, Lipids, Activity and Sex Hormones
study. Women were recruited by letters to physicians and
flyers in the community, medical center, senior centers and
private medical practices. Flyers stated that women had to
be postmenopausal and have one or more cardiac risk factors
(age, hypertension, hypercholesterolemia, smoking, diabetes
or low level of physical activity). All women had their last
menses $1 year before enrollment (46 women had under-
gone surgical menopause). Women with known CHD were
excluded from the study. All study participants gave written,
informed consent. The protocol was approved by the
Committee on Human Research at the University of Cali-
fornia, San Francisco (UCSF).
EBCT. All studies were performed with a specific scanner
(Imatron C-150). Patients were studied in the supine
position. After localization of the main pulmonary artery,
contiguous slices to the apex of the heart were obtained with
ECG-gated triggering at 80% of the RR interval. Coronary
foci with a computed tomographic density $130 Houns-
field Units (HU) and an area of four or more adjacent pixels
($1.03 mm2) were determined to represent coronary artery
calcium (20). A region of interest was manually selected
around each visible lesion within each coronary artery.
Computer-acquired measurements of lesion area in square
millimeters and the maximal HU number of each region of
interest were recorded. A density score was determined
based on maximal HU number as follows: 1 5 130 to 199
HU, 2 5 200 to 299 HU, 3 5 300 to 399 HU, 4 $ 400
HU. A score for each region of interest was calculated by
multiplying density score by area. A calcium score was
calculated as the sum of all lesion scores per the protocol of
Agatston et al. (25).
Evaluation of cardiac risk factors. LP(A) ASSAY. Blood was
drawn following a 10-h to 12-h fast for assay of Lp(a). The
Lp(a) content of serum samples was determined by an
ELISA technique developed in the Cardiovascular Research
Institute of UCSF to quantify the apolipoprotein B-100
moiety of the Lp(a) lipoprotein. A monoclonal antibody to
the protein(a) moiety (Biodesign International, Saco,
Maine) is used to coat microtiter plates at 5° for 16 h at a
protein content of 10 mg/ml in phosphate-buffered saline
0.05 M phosphate, 0.15 M sodium chloride, pH 7.2. The
plates are blocked as above for 1 h at 20° using 200 ml of
phosphate-buffered saline, containing 3% bovine serum
albumin (Sigma, St. Louis). Serum samples are diluted 200-
to 320-fold in phosphate-buffered saline as above, contain-
ing 0.1% bovine serum albumin. A standard curve is
constructed by diluting ultracentrifugally purified human
serum LDL (1.055 . d , 1.020 g/cm3) in the same buffer.
After incubation of the samples and standards in the coated
plates for 5 h at 37°, they are washed five times with 300 ml
of phosphate-buffered saline, as above. A 2000-fold dilution
of goat anti-human apolipoprotein B-100 conjugated with
horseradish peroxidase is added to each well for 1 h at 37°,
followed by a wash as above. Color developed with tetram-
ethyl benzidine is quantified in an automated plate reader
(Molecular Devices; Sunnyvale, CA) at 450 nm. The
content of Lp(a) is reported in nM/liter of Lp(a)-associated
apo B-100.
OTHER CARDIAC RISK FACTORS. We evaluated cardiac risk
factors: age, diabetes, hypertension, smoking and LDL
cholesterol, as validated in the Framingham study (26), as
well as body mass index and physical activity.
Age was evaluated as a continuous and ordinal variable.
Diabetes was considered present if a patient was treated
with insulin or oral agents or had a fasting glucose level of
$126 mg/dl. Hypertension was defined as a blood pressure
.140/90 mm Hg or current use of antihypertensive drugs.
Smoking was evaluated using the following scoring system:
0, nonsmoker; 1, quit .3 years ago; 2, quit #3 years ago; 3,
current smoker. As hormone replacement therapy has been
shown to affect Lp(a) levels (27), its use and duration were
included in the analyses. Hormone replacement therapy was
evaluated as the duration of therapy (estrogen or estrogen
and progesterone). Body mass index was computed as
weight (in kilograms) divided by height (in meters) squared.
Physical activity was determined by interview. It was quan-
tified using modified Paffenberger’s method (metabolic
equivalents (Mets)zhour/week) (28). This score quantifies
maximum metabolic energy intensity 3 hours duration per
week for a wide range of recreational activities that had been
maintained during at least 75% of the preceding year.
Total cholesterol and triglyceride levels were measured by
automated fluorescence analysis (Hoffmann-La Roche Inc;
Abbreviations and Acronyms
CHD 5 coronary heart disease
EBCT 5 electron beam computed tomography
HDL 5 high-density lipoprotein
HU 5 Hounsfield Units
LDL 5 low-density lipoprotein
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UCSF 5 University of California, San Francisco
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Nutley, New Jersey). High-density lipoprotein (HDL) cho-
lesterol was measured in like manner after precipitation of
apolipoprotein B containing lipoproteins with dextran sul-
fate and manganese (29). The LDL cholesterol level was
computed with the formula of Friedwald et al. (30). Only
LDL cholesterol was assessed in data analysis among the
four lipid variables (total cholesterol, triglycerides, HDL
cholesterol and LDL cholesterol) because multicollinearity
can be produced statistically if all four lipid variables were
selected. Treatment with any cholesterol-lowering medica-
tions was held for at least one week before the blood test.
The number of cardiac risk factors (age, hypertension,
hypercholesterolemia, smoking, diabetes, obesity and low
level of physical activity) was also calculated in each patient.
The following criteria were used to score risk factors. Age
.60 years was considered to be risk factor as well as
hypertension and diabetes as defined above. Smoking was
defined as current smoker or quit #3 years ago. Hypercho-
lesterolemia was defined as LDL cholesterol $160 mg/dl.
Obesity was defined as body mass index .25 kg/m2. Low
level of physical activity was defined as Metszhour/week
,15.
Data analysis. An unpaired Student t test and chi-square
analyses were performed to examine differences in mean
calcium scores, prevalence of detectable calcium for each age
group and Lp(a) level between the patients with and
without hormone replacement therapy.
To determine the significant and independent risk factors
for coronary calcium in asymptomatic postmenopausal
women, all risk factors, including Lp(a), were analyzed by
multivariate analysis (general linear models). The dependent
variable was the calcium score. Independent variables were
as follows: age, Lp(a), LDL cholesterol, hypertension,
smoking, diabetes, body mass index, physical activity and
duration of hormone replacement therapy. Multivariate
analyses also were performed in two subgroups: in women
.60 years and in the subjects with significant coronary
calcium deposits (calcium score $50). Software (SAS for
Windows v6.12) was used for these multivariate analyses.
All values are expressed as mean 6 SD unless otherwise
noted. P values ,0.05 were considered significant.
RESULTS
Patient characteristics. Age ranged from 36 to 88 years
(Table 1). Eighty-seven patients (49%) were taking hor-
mone replacement therapy for a mean of 8.6 6 9.0 years. In
the patients using hormone replacement therapy, 46% used
combination therapy (progesterone and estrogen). The
mean number of measured cardiac risk factors, in addition
to postmenopausal status in this population, was 1.7 6 0.9.
Prevalence of coronary calcium. Calcium scores ranged
from 0 to 2,618 with 44% showing no coronary calcium, a
calcium score of zero (Table 1). Adequate studies for
coronary calcium were obtained in all patients. An increase
in the prevalence of detectable calcium deposits was seen
with age (Fig. 1). The prevalence of detectable calcium was
significantly higher in the 70- to 89-year-old group com-
pared with the younger groups (Fig. 1). Similarly, the total
amount of coronary calcium increased with age (Table 2).
Relationship between risk factors, including Lp(a) and
coronary calcium in postmenopausal women. Age (p 5
0.006), smoking (p , 0.001), diabetes mellitus (p , 0.001)
and hypertension (p 5 0.012) were found to be significantly
Figure 1. Percentage of women with detectable coronary calcium
(calcium score greater than zero) by age group. *p , 0.05 vs. 50 to
59 years group.
Table 1. Patient Characteristics
Distribution or Mean
6 SD
Coronary artery calcium score 88 6 255
no deposits (calcium score 5 0) 79 (44%)
Age (yr) 64 6 8
Smoking
No 88 (49%)
ex . 3 yr 76 (43%)
ex # 3 yr 3 (2%)
Current 10 (6%)
Diabetes
Yes 13 (7%)
No 165 (93%)
Hypertension
Yes 63 (35%)
No 115 (65%)
Hormone replacement therapy
Yes 87 (49%)
Duration (yr) 8.6 6 9.0
Body mass index (kg/m2) 24.3 6 4.0
Total cholesterol (mg/dl) 259 6 56
LDL cholesterol (mg/dl) 167 6 51
HDL cholesterol (mg/dl) 62 6 19
Lp(a) cholesterol (mg/dl) 110 6 160
Physical activity (Metszh/wk) 23.3 6 29.4
Current 5 current smoker; ex 5 ex-smoker; Lp(a) 5 lipoprotein(a); Mets 5
metabolic equivalents.
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associated with coronary calcium scores in postmenopausal
women, whereas Lp(a) (p 5 0.480) and the other risk
factors analyzed were not correlated with the calcium score.
The same associations were found in the subset of women
age .60 years (n 5 118). In the subset of women with
significant calcium deposits (n 5 52), age (p 5 0.039),
smoking (p , 0.001), diabetes mellitus (p 5 0.043) and
LDL cholesterol (p 5 0.018) were found to be associated
with coronary calcium score. Lipoprotein(a) (p 5 0.117)
and the other risk factors analyzed were not correlated with
the calcium score.
There were no significant differences in Lp(a) levels
between the patients with and without hormone replace-
ment therapy (Table 3).
DISCUSSION
In this study, Lp(a) levels did not correlate with calcium
score measured by EBCT as a marker for coronary athero-
sclerosis in asymptomatic postmenopausal women. This
lack of an association was consistent in subgroup analysis of
only older subjects (age .60 years) or of only subjects with
significant coronary calcium deposits (calcium score $50).
Thus, Lp(a) may not be an independent risk factor for
CHD in asymptomatic postmenopausal women.
Lp(a) and atherosclerosis. Lipoprotein(a) interferes with
fibrinolysis. The mechanism is thought to involve compe-
tition with plasminogen for binding sites on cells and fibrin
because of the structural homology between apolipopro-
tein(a) and plasminogen (31,32). The clinical correlates of
impaired thrombolysis in patients with high levels of Lp(a)
include the detection of increased tissue plasminogen acti-
vator inhibitor levels, the decreased activity of tissue plas-
minogen activator in young survivors of myocardial infarc-
tion and the detection of increased Lp(a) levels in survivors
of myocardial infarction without recanalization of their
infarct-related arteries (33). Additionally, Lp(a) is an LDL-
like lipoprotein that appears to exert direct atherogenic
effect (31,34–36). In histologic studies, Lp(a) and the (a)
protein moiety have been identified in atherosclerotic le-
sions, and elevated levels of Lp(a) in serum have been
associated with increased detection of both protein(a) and
apolipoprotein B in the arterial wall (31,35,36). Thus, there
are at least two possible mechanisms—prothrombotic effects
and proatherogenic effects—by which Lp(a) may promote
atherosclerosis.
Lp(a) and CHD. Many studies have reported a relation-
ship between Lp(a) and CHD. The first study to show a
significant relationship was performed in 86 women and
216 men by Dahle´n et al. (37), using coronary angiography
as the end point for CHD. Similar relationships were seen
in other studies (38,39). Three large surveys in men showed
that higher levels of Lp(a) were correlated with an increase
in cardiac events—fatal or nonfatal CHD (37,40,41). Sim-
ilarly, a recent prospective study of 2,191 young to middle-
age men found that elevated plasma Lp(a) was an indepen-
dent risk factor for the development of premature CHD
measured by cardiac events (42). Data from 3,103 women in
the Framingham Heart Study showed an increased relative
risk for myocardial infarction associated with higher levels
of Lp(a). Elevated plasma Lp(a) was a strong, independent
predictor of myocardial infarction, intermittent claudica-
tion, cerebrovascular disease and total CHD (18). More
recently, Schwartzman et al. (43) also reported that higher
plasma Lp(a) levels correlated with significant coronary
artery disease stenoses.
However, other studies have shown a lack of association
between Lp(a) and CHD, as seen in the present study. The
Helsinki Heart Study found that Lp(a) did not significantly
predict CHD in 4,081 hyperlipidemic men (44). In a large
study of 14,916 men, Ridker et al. (45) showed that Lp(a)
was unrelated to fatal and nonfatal myocardial infarction. In
a cross-sectional analysis of 1,202 men and 1,512 women
.60 years of age in Australia, Simons et al. (46) found no
significant increase in Lp(a) in patients with CHD. Re-
cently, Cantin et al. (47) reported that Lp(a) is not an
independent risk factor for ischemic heart disease in men.
They have suggested that elevated Lp(a) may be a risk factor
for CHD only in men with elevated LDL cholesterol levels,
whereas it is not an independent risk factor in the general
population. Using criteria from the Atherosclerosis Risk in
Communities (ARIC) study criteria (48), most of our study
cohort were in a low-risk lipid group (LDL cholesterol
Table 2. Prevalence of Detectable Calcium (score . 0) and
Mean Calcium Score
Age (yr)
Calcium
Prevalence
Mean Calcium
Score
30–49 38% (3/8) 4 6 10
50–59 48% (21/44) 26 6 72
60–69 54% (44/82) 56 6 132
70–89 70% (31/44) 225 6 450*
*p , 0.05 vs. 50 to 59, or 60 to 69 years group.
Table 3. Relation of Lipoprotein(a) and the Other Variables to
Calcium Score
Variables SPRC p Value
Lipoprotein(a) 0.057 0.398
Age 0.179 0.009
Smoking 0.224 0.007
Diabetes 0.421 , 0.001
Hypertension 0.185 0.005
Atherogenic index (TC/HDL) 0.023 0.751
Hormone replacement therapy 0.010 0.875
Body mass index (kg/m2) 20.116 0.948
Physical activity (Metszh/wk)
Multiple R2 5 0.328
0.110 0.075
Mets 5 metabolic equivalents; SPRC 5 standardized partial regression coefficient;
other abbreviations as in Table 1.
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,160 mg/dl or HDL cholesterol .35 mg/dl), and therefore
our findings in women are consistent with the report of
Cantin et al. (47) in a male population.
Thus, there is conflicting epidemiologic evidence linking
Lp(a) to risk of CHD. However, in the previous studies, the
definition of CHD was occurrence of events or significant
coronary stenosis detected by coronary angiography. There-
fore, these patients had relatively advanced coronary disease.
In the present study, we used calcium burden measured by
EBCT as a marker for atherosclerosis. Electron beam
computed tomography is a noninvasive method to identify
early coronary atherosclerosis, enabling us to recruit asymp-
tomatic patients. Electron beam computed tomography data
have been suggested to be more valuable in women with
suspected CHD, because they are gender independent (7),
whereas other noninvasive studies such as treadmill testing
have been shown to be less accurate in women (8). The
relationship of Lp(a) to CHD has been more closely studied
in men than women (49). This report offers new insights
into the relationship between atherosclerosis measured by
coronary calcium deposits and risk factors including Lp(a)
in asymptomatic postmenopausal women.
Other studies of healthy populations such as the Physi-
cians’ Health Study also failed to show an association
between Lp(a) and CHD (45,50). Perhaps the lack of
association of Lp(a) and markers of early CHD can be
explained because Lp(a) acts substantially through its anti-
fibrinolytic activity. Thus, it would be expected to correlate
best with severe disease involving plaque rupture and
thrombotic events.
Coronary calcium deposits. Studies on the mechanisms of
deposition of calcium in atherosclerotic lesions indicate that
it is a process analogous to the formation of bone spicules
(51,52). Furthermore, it appears that it involves cells of
special embryonic lineage. It can be expected that coronary
calcification is not merely a direct consequence of athero-
genesis but rather may depend on the presence of specific
determinants independent of the central processes active in
plaque formation. Such determinants may be of much
greater importance to the development of coronary calcifi-
cation than the level of Lp(a), possibly obscuring a contri-
bution by Lp(a) per se.
The prevalence of coronary calcium deposits in our
subjects was lower than that in the previous reports
(5,53,54). This likely reflects the fact that our population
comprised healthy postmenopausal women. However, there
was no relationship between Lp(a) and coronary calcium
deposits even when the group of women with significant
calcium deposits (calcium score $50 [5,53,54]) was ana-
lyzed separately. Others (5,55) have reported that screening
for coronary calcium deposits should be used in older
women (.60 years). We analyzed coronary calcium deposits
and Lp(a) in this subgroup and found no relationship.
Traditional CHD risk factors. This study confirms that
age, hypertension, smoking and diabetes are independently
associated with coronary calcium, consistent with previous
reports (5,53,56,57). However, in our study, overall there is
no significant correlation between LDL cholesterol and
coronary calcium deposits when the entire cohort was
analyzed. Other studies have shown significant correlations
between hypercholesterolemia and coronary calcium depos-
its (5,25,41,53). The reasons for this discrepancy may be
that our study population had lower calcium scores, lower
number of risk factors and presumably less atherosclerosis
than patients in previous reports (5,53). In the subgroup
with the higher burden of arterial calcium, a significant
correlation of LDL cholesterol with calcium deposits was
observed. Moreover, although we held treatment with
cholesterol-lowering medications for one week before mea-
suring the serum cholesterol level, a longer period of
medications might have led to higher levels of LDL,
affording a better opportunity to detect a relationship. Most
agents used to treat hypercholesterolemia have little effect
on levels of Lp(a) (50).
Hormone replacement therapy. In this study, we found
no relationship between use of hormone replacement ther-
apy and coronary calcium. However, McLaughlin et al. (54)
recently reported a significant relationship between hor-
mone replacement therapy and coronary calcium deposits
estimated by EBCT. The reasons for this discrepancy may
be that, in our study, hormone replacement therapy was
evaluated by duration of use, whereas the previous study
(54) treated hormone replacement therapy as present or
absent.
We also found no relationship between the hormone
replacement therapy and Lp(a) levels. This differs from the
results of the Postmenopausal Estrogen/Progestin Interven-
tions (PEPI) Trial (58). In PEPI, Lp(a) levels were signif-
icantly decreased (mean reduction of 17% to 23%) in the
hormone replacement group compared with the placebo
group (27).
Study limitations. Electron beam computed tomography
calcium scores have been shown to be associated with
coronary atherosclerosis in studies of predominantly male
patients with relatively high risk for CHD (59–61). How-
ever, this association may not be present in asymptomatic
postmenopausal women. However, EBCT may be clinically
more valuable in women with suspected disease because
other noninvasive studies have been shown to be less
accurate with women than men (7). Thus, we investigated
the links between risk factors in women and EBCT calcium
scores in this study.
The sample size in our study is relatively small. In
addition, we studied asymptomatic postmenopausal women
who agreed to undergo a treadmill test, and our conclusions
can be applied only to this population. To confirm our
findings, large population-based studies should be under-
taken.
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CONCLUSIONS
This study demonstrated a lack of association of Lp(a) with
coronary calcium deposits measured by EBCT in asymp-
tomatic postmenopausal women.
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